Abstract

Multiple sclerosis is the most common disabling neurological disease of young adults. The ability to impact the quality of life of patients with multiple sclerosis should not only incorporate therapies that are disease modifying, but should also include a course of action for the global multidisciplinary management focused on quality of life and functional capabilities.

Original languageEnglish (US)
Pages (from-to)83-98
Number of pages16
JournalTherapeutic Advances in Neurological Disorders
Volume4
Issue number2
DOIs
StatePublished - Mar 2011

Keywords

  • fatigue
  • multiple sclerosis
  • neurogenic bowel and bladder
  • spasticity
  • symptomatic therapy
  • visual symptoms

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Symptomatic therapy in multiple sclerosis'. Together they form a unique fingerprint.

Cite this